Cancer and Metastasis Reviews

Papers
(The median citation count of Cancer and Metastasis Reviews is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Editorial Expression of Concern: Targeting microRNAs as a promising anti-cancer therapeutic strategy against traffic-related air pollution-mediated lung cancer216
Immunotherapy for leptomeningeal disease from solid tumors: current clinical outcomes and future opportunities148
The impact of tumor microenvironment: unraveling the role of physical cues in breast cancer progression111
Clonal tracking in cancer and metastasis102
CAR T-cell therapy for B-cell lymphomas: outcomes and resistance mechanisms80
New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions78
The functions and modifications of tRNA-derived small RNAs in cancer biology77
Obesity and cancer70
Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective67
Regulation of dormancy during tumor dissemination: the role of the ECM66
Targeting lipid metabolism in cancer: neuroblastoma52
The paradoxical role of inositol in cancer: a consequence of the metabolic state of a tumor50
CAR T-cell therapy to treat multiple myeloma: current state and future directions49
Progression and metastasis of small cell lung carcinoma: the role of the PI3K/Akt/mTOR pathway and metabolic alterations49
Cell-cell interactions mediating primary and metastatic breast cancer dormancy48
Immunotherapy for triple negative breast cancer: the end of the beginning or the beginning of the end?48
Natural killer cells in neuroblastoma: immunological insights and therapeutic perspectives48
The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer48
p73 isoforms meet evolution of metastasis46
KISS1 metastasis suppressor in tumor dormancy: a potential therapeutic target for metastatic cancers?41
Healthcare disparities, screening, and molecular testing in the changing landscape of non–small cell lung cancer in the United States: a review40
TRIM-endous functional network of tripartite motif 29 (TRIM29) in cancer progression and beyond40
A multidisciplinary perspective on the complex interactions between sleep, circadian, and metabolic disruption in cancer patients39
Preface37
Targeting microRNAs as a promising anti-cancer therapeutic strategy against traffic-related air pollution-mediated lung cancer36
Biography—Mathieu Boissan, Pharm.D., Ph.D36
LGR5: An emerging therapeutic target for cancer metastasis and chemotherapy resistance34
Neuropeptide Y in cancer—biological functions and potential clinical implications33
Biographies31
How circulating tumor cluster biology contributes to the metastatic cascade: from invasion to dissemination and dormancy31
Role of Neuropilin-2-mediated signaling axis in cancer progression and therapy resistance31
Biographies31
Short-chain fatty acids in cancer pathogenesis30
The multifaceted mechanisms of malignant glioblastoma progression and clinical implications30
Cross-talk between the microbiome and chronic inflammation in esophageal cancer: potential driver of oncogenesis29
The role of cancer cell bioenergetics in dormancy and drug resistance28
Systematic review of the receptor tyrosine kinase superfamily in neuroblastoma pathophysiology27
Clusterin: a marker and mediator of chemoresistance in colorectal cancer27
Immunomodulatory role of oncogenic alterations in non-small cell lung cancer: a review of implications for immunotherapy27
Helicobacter pylori–activated fibroblasts as a silent partner in gastric cancer development26
Tumor necrosis factor superfamily signaling: life and death in cancer26
Clinical interventions to break the obesity and cancer link: a narrative review25
The emerging roles of histone demethylases in cancers25
Epigenetic reprogramming of T cells: unlocking new avenues for cancer immunotherapy24
Tissue-engineered patient-derived osteosarcoma models dissecting tumour-bone interactions24
The tumor microenvironment in pancreatic ductal adenocarcinoma: current perspectives and future directions24
Vaping and tumor metastasis: current insights and progress24
Kenneth V. Honn, Ph.D. (1946–2023)23
Debris-stimulated tumor growth: a Pandora’s box?23
Heterogeneity and tumor evolution reflected in liquid biopsy in metastatic breast cancer patients: a review23
Functional and clinical roles of stromal PDGF receptors in tumor biology23
Dormancy, stemness, and therapy resistance: interconnected players in cancer evolution23
Carcinoma of unknown primary (CUP): an update for histopathologists23
The role of mitochondria in tumor metastasis and advances in mitochondria-targeted cancer therapy23
OX40/OX40 ligand and its role in precision immune oncology22
Racial disparity in prostate cancer: an outlook in genetic and molecular landscape22
PRUNE1 and NME/NDPK family proteins influence energy metabolism and signaling in cancer metastases22
Inflammatory bowel disease and carcinogenesis22
Oncogenic functions of the FOXC2 transcription factor: a hallmarks of cancer perspective21
New progress of tuberculosis scar carcinoma21
The strict regulation of HIF-1α by non-coding RNAs: new insight towards proliferation, metastasis, and therapeutic resistance strategies21
Ferroptosis: iron release mechanisms in the bioenergetic process21
CTGF (CCN2): a multifaceted mediator in breast cancer progression and therapeutic targeting21
Biographies20
HOXA9 transcription factor is a double-edged sword: from development to cancer progression20
UCP2 and pancreatic cancer: conscious uncoupling for therapeutic effect20
Current state-of-the-art on ganglioside-mediated immune modulation in the tumor microenvironment19
Is cancer an intelligent species?19
Understanding metabolic alterations and heterogeneity in cancer progression through validated immunodetection of key molecular components: a case of carbonic anhydrase IX19
Multifaceted role of the DNA replication protein MCM10 in maintaining genome stability and its implication in human diseases19
Classification of anticancer drugs: an update with FDA- and EMA-approved drugs19
Metastasis suppressor genes and their role in the tumor microenvironment18
Metastasis suppressor genes in clinical practice: are they druggable?18
The role of circular RNA during the urological cancer metastasis: exploring regulatory mechanisms and potential therapeutic targets18
Recent advances in synthetic strategies and SAR of thiazolidin-4-one containing molecules in cancer therapeutics18
De- “bug”-ing the microbiome in lung cancer17
Oncogenic super-enhancers in cancer: mechanisms and therapeutic targets17
Lost at SCLC: a review of potential platinum sensitizers17
Oncobiology and treatment of breast cancer in young women17
Correction to: The gut microbiome, immune check point inhibition and immune‑related adverse events in non‑small cell lung cancer17
The diversity of natural killer cell functional and phenotypic states in cancer16
Correlative studies reveal factors contributing to successful CAR-T cell therapies in cancer16
The role of bone marrow adipocytes in cancer progression: the impact of obesity15
The cure from within? a review of the microbiome and diet in melanoma15
The biological function of extracellular vesicles in prostate cancer and their clinical application as diagnostic and prognostic biomarkers15
Glycosylation as a regulator of site-specific metastasis15
Influence of antibody–drug conjugate cleavability, drug-to-antibody ratio, and free payload concentration on systemic toxicities: A systematic review and meta-analysis15
Oncohistones and disrupted development in pediatric-type diffuse high-grade glioma15
Metabolic factors associated with the prognosis of oligometastatic patients treated with stereotactic body radiotherapy15
Where is Waldo? or find the platelet14
Preface14
Preface14
Role of myeloid-derived suppressor cells in tumor recurrence14
White adipose tissue-derived factors and prostate cancer progression: mechanisms and targets for interventions14
Biography—Mikhail Kolonin14
The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer13
Liquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumors13
Biographies13
The role of metabolic ecosystem in cancer progression — metabolic plasticity and mTOR hyperactivity in tumor tissues13
Notch signaling in malignant gliomas: supporting tumor growth and the vascular environment13
The role of the metabolite cargo of extracellular vesicles in tumor progression13
The role of obesity and bariatric surgery-induced weight loss in breast cancer13
Cancer cell plasticity, stem cell factors, and therapy resistance: how are they linked?13
Multiomics approach towards characterization of tumor cell plasticity and its significance in precision and personalized medicine12
Considerations for modelling diffuse high-grade gliomas and developing clinically relevant therapies12
Potential biomarkers for immunotherapy in non-small-cell lung cancer12
Cancer metastasis under the magnifying glass of epigenetics and epitranscriptomics12
The timing of adiposity and changes in the life course on the risk of cancer12
Therapeutic importance and diagnostic function of circRNAs in urological cancers: from metastasis to drug resistance12
Nanotechnology-aided advancement in the combating of cancer metastasis12
Epigenetic drugs in cancer therapy12
Insights into the role of senescence in tumor dormancy: mechanisms and applications11
The vulnerable primed cancer stem cells in disguise: demystifying the role of Maspin11
Epigenetic control of pancreatic cancer metastasis11
The roles of periostin derived from cancer-associated fibroblasts in tumor progression and treatment response11
Minimally invasive biomarkers for triaging lung nodules—challenges and future perspectives11
Correction to: Connecting the human microbiome and pancreatic cancer10
Preface10
Models of pancreatic ductal adenocarcinoma10
Natural compounds targeting nuclear receptors for effective cancer therapy10
Molecular profile of metastasis, cell plasticity and EMT in pancreatic cancer: a pre-clinical connection to aggressiveness and drug resistance10
Using ultrasound and microbubble to enhance the effects of conventional cancer therapies in clinical settings10
Tumor ablation induced anti-tumor immunity: destruction of the tumor in situ with the aim to evoke a robust anti-tumor immune response10
Epigenetic changes and the dynamic heterogeneity of the metastatic phenotype – challenges ahead9
Oral delivery of RNAi for cancer therapy9
The emerging role of the gut microbiome in cancer cell plasticity and therapeutic resistance9
Melanoma in people living with HIV: Immune landscape dynamics and the role of immuno- and antiviral therapies9
Targeting vimentin: a multifaceted approach to combatting cancer metastasis and drug resistance9
Evolving strategies for addressing CAR T-cell toxicities9
Epigenetic markers and therapeutic targets for metastasis9
Obesity and cancer—extracellular matrix, angiogenesis, and adrenergic signaling as unusual suspects linking the two diseases9
Glioblastoma stem cell metabolism and immunity9
Advancements in gene therapies targeting mutant KRAS in cancers9
Recapitulating the potential contribution of protein S-palmitoylation in cancer9
What do cellular responses to acidity tell us about cancer?9
Targeting miRNA and using miRNA as potential therapeutic options to bypass resistance in pancreatic ductal adenocarcinoma8
Neuronal mimicry in tumors: lessons from neuroscience to tackle cancer8
Retraction Note: EET signaling in cancer8
The fibro-adipogenic progenitor APOD+DCN+LUM+ cell population in aggressive carcinomas8
Host-microbe interactions and outcomes in multiple myeloma and hematopoietic stem cell transplantation8
Obesity, cancer risk, and time-restricted eating8
0.44939398765564